Humacyte announced it has completed its first commercial sale of Symvess, a large-diameter bioengineered vessel, to a military treatment facility. The sale was made to Brooke Army Medical Center in San Antonio, Texas, which the company said is part of the Defense Health Agency network.
According to Humacyte, Symvess is produced using its proprietary Humacyl platform, which aims to create human acellular vessels (HAVs) designed for use in multiple vascular procedures. The company claims these vessels offer durability and resistance to infection, potentially reducing complications compared to synthetic grafts.
The company noted this milestone follows the June launch of Symvess in the United States, after receiving authorization under a Humanitarian Device Exemption from the FDA. Humacyte said it plans to expand availability to other hospitals and expects growing adoption in military and civilian medical centers.
Humacyte also stated it is continuing clinical development of its smaller-diameter 6mm HAV, intended for patients with chronic limb-threatening ischemia and for use in vascular trauma repair. The company claims these developments support its broader goal of providing regenerative medicine-based vascular replacement options.
The financial terms of the sale were not disclosed. The company highlighted the agreement as part of its commercial rollout strategy to introduce Symvess to healthcare providers seeking alternatives to existing vascular grafts.
